Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
- Sponsor
- Imperial College London
- Study ID
- NCT03371862
- Phase
- PHASE2
- Status
- Withdrawn
Conditions
- Short Bowel Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide Pen Injector [Victoza] — DRUGPilot study of liraglutide in patients with short bowel.
Study Details
Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.
Key Dates
- Start date
- Oct 20, 2017
- Status verified
- Aug 2020
- Primary completion
- Aug 6, 2020
- Completion
- Sep 30, 2020
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Test group
Primary Outcome Measure
Improvement in parenteral support [ Time Frame: 20 weeks post start of drug ]
Related Studies
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruiting · Sanford Health · Sioux Falls, South Dakota
- A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORBRecruiting · Boston Children's Hospital · Boston, Massachusetts
- Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF SubjectsPHASE2 · Recruiting · Hanmi Pharmaceutical Company Limited · Boston, Massachusetts
- A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel SyndromeRecruiting · Eclipse Regenesis, Inc. · Palo Alto, California